- Home
- MTAL vs IMNM Comparison
MTAL vs IMNM Comparison
Compare MTAL & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTAL
- IMNM
- Stock Information
- Founded
- MTAL 2021
- IMNM 2006
- Country
- MTAL Jersey
- IMNM United States
- Employees
- MTAL N/A
- IMNM N/A
- Industry
- MTAL Blank Checks
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- MTAL Finance
- IMNM Health Care
- Exchange
- MTAL Nasdaq
- IMNM Nasdaq
- Market Cap
- MTAL 690.2M
- IMNM 748.3M
- IPO Year
- MTAL 2021
- IMNM 2020
- Fundamental
- Price
- MTAL $12.12
- IMNM $8.75
- Analyst Decision
- MTAL Hold
- IMNM Strong Buy
- Analyst Count
- MTAL 2
- IMNM 5
- Target Price
- MTAL $12.63
- IMNM $26.40
- AVG Volume (30 Days)
- MTAL 816.1K
- IMNM 874.4K
- Earning Date
- MTAL 08-09-2025
- IMNM 08-11-2025
- Dividend Yield
- MTAL N/A
- IMNM N/A
- EPS Growth
- MTAL N/A
- IMNM N/A
- EPS
- MTAL N/A
- IMNM N/A
- Revenue
- MTAL $340,736,000.00
- IMNM $10,938,000.00
- Revenue This Year
- MTAL $20.81
- IMNM N/A
- Revenue Next Year
- MTAL $21.10
- IMNM $349.38
- P/E Ratio
- MTAL N/A
- IMNM N/A
- Revenue Growth
- MTAL 114.30
- IMNM N/A
- 52 Week Low
- MTAL $7.69
- IMNM $5.15
- 52 Week High
- MTAL $14.93
- IMNM $16.81
- Technical
- Relative Strength Index (RSI)
- MTAL 64.91
- IMNM 48.43
- Support Level
- MTAL $11.94
- IMNM $9.02
- Resistance Level
- MTAL $12.29
- IMNM $9.91
- Average True Range (ATR)
- MTAL 0.16
- IMNM 0.55
- MACD
- MTAL -0.11
- IMNM -0.08
- Stochastic Oscillator
- MTAL 32.74
- IMNM 9.37
About MTAL Metals Acquisition Limited
MAC Copper Ltd is a company focused on operating and acquiring metals and mining businesses in high-quality, stable jurisdictions that are critical in the electrification and decarbonization of the world-wide economy.
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.